secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004194
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC outlines 2023 milestones: initial Phase 1b data expected H2 2023 for three programs
--------------------------------------------------------------------------------

- Initial Phase 1b data expected H2 2023 for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2 cancers), ORIC-944 (prostate cancer).
- Pfizer invested $25M in ORIC common stock as part of ORIC-533 clinical collaboration.
- Cash and investments $228M as of Dec 31, 2022; runway into H1 2025.
- Selected PLK4 inhibitor as development candidate for breast cancer (TRIM37-amplified) in Q4 2022.
- All three clinical programs dose-escalating steadily without reaching MTD; global site expansion ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/0001193125-23-004194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523004194/d448025d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer